92197-36-9

Usage

Chemical class

Piperidine derivatives
BHMP is a compound that belongs to the class of piperidine derivatives, which are organic compounds containing a six-membered nitrogen-containing ring.
2. Pharmaceutical intermediate
1-Benzyl-4-hydroxyMethylpiperidin-4-ol is commonly used as a pharmaceutical intermediate, meaning it is a substance used in the synthesis of various medications.
3. Molecular structure

Piperidine ring

BHMP has a piperidine ring structure, which is a six-membered nitrogen-containing ring.

Benzyl group

A benzyl group is attached to the piperidine ring, which is a phenyl group connected to a methyl group.

Hydroxymethyl group

A hydroxymethyl group is also attached to the piperidine ring, which is a methyl group connected to a hydroxyl group (-OH).
4. Antioxidant potential
BHMP has been studied for its potential use as an antioxidant, which means it may help neutralize harmful free radicals in the body and protect cells from damage.
5. Inhibition of harmful free radicals
The compound has shown promise in inhibiting the formation of harmful free radicals, which can contribute to various diseases and aging processes.
6. Neurodegenerative disease treatment
1-Benzyl-4-hydroxyMethylpiperidin-4-ol has demonstrated potential in the treatment of neurodegenerative diseases, such as Alzheimer's and Parkinson's, by potentially protecting neurons from damage and degeneration.
7. Anti-inflammatory properties
BHMP has also shown promise as an anti-inflammatory agent, which means it may help reduce inflammation and swelling in the body, potentially providing relief from various inflammatory conditions.
8. Ongoing research
1-Benzyl-4-hydroxyMethylpiperidin-4-ol continues to be an active area of research due to its potential pharmacological properties and potential application in various therapeutic areas.

Upstream product

• 60437-30-1 4-hydroxy-4-(methoxycarbonyl)-1-(phenylmethyl)piperidine 
• 19867-34-6 N-benzyl-1-oxa-6-azaspiro[2,5]-octane 
• 109105-86-4 N-benzyl-4-methylenepiperidine 
• 3612-20-2 1-phenylmethyl-4-piperidone 

Downstream Products

• 89584-31-6 4-(hydroxymethyl)piperidin-4-ol 
• 477721-43-0 1-benzyl-4-(4-cyanophenoxymethyl)piperidin-4-ol 
• 1239360-35-0 (S)-1-{2-[1-(4-fluorophenyl)indolylethylamino]-6-(aminopyrazine-2-ylamino)pyrimidinecarboxylic-4-yl}-4-(hydroxymethyl)-4-ol 
• 1239363-20-2 (S)-1-{6-chloro-2-[1-(4-fluorophenyl)ethylamino]pyrimidin-4-yl}-4-(hydroxymethyl)piperidin-4-ol 
• 389889-80-9 tert-butyl 4-hydroxy-4-(hydroxymethyl)piperidine-1-carboxylate 
• 1445790-84-0 C₁₉H₁₈F₄N₂O₅S 
• 1239360-42-9 (S)-8-{2-[1-(4-fluorophenyl)ethyl]-6-(pyrazin-2-ylamino)pyrimidin-4-yl}-1,3-dioxo-8-azaspiro[4.5]decane-2-one 
• 240401-25-6 4-hydroxy-4-hydroxymethylpiperidine hydrochloride 

Relevant academic research and scientific papers

HEPATITIS B ANTIVIRAL AGENTS

The present invention includes a method of inhibiting, suppressing or preventing HBV infection in an individual in need thereof, comprising administering to the individual a therapeutically effective amount of at least one compound of the invention.

Selected CGRP-antagonists, process for preparing them and their use as pharmaceutical compositions

The present invention relates to the CGRP antagonists of general formula wherein A, X, Q and R1 to R3 are defined as in claim 1, the tautomers, the isomers, the diastereomers, the enantiomers, the hydrates, mixtures and salts thereof and the hydrates of the salts, particularly the physiologically acceptable salts thereof with inorganic or organic acids, pharmaceutical compositions containing these compounds, their use and processes for preparing them.

SELECTED CGRP ANTAGONISTS, METHODS FOR THE PRODUCTION THEREOF, AND USE THEREOF AS MEDICAMENTS

The invention relates to CGRP antagonists of general formula (I), wherein A, X, Q, and R1 to R3 are defined as indicated in claim 1, the tautomers, isomers, diastereomers, enantiomers, hydrates, mixtures, and salts thereof, and the hydrates of the salts, especially the physiologically acceptable salts thereof with inorganic or organic acids, medicaments containing said compounds, the use thereof, and methods for the production thereof.

QUINOLONE ANTIBACTERIAL AGENTS

Compounds of formula (I, II, III, IV, V, and VI) and methods for their preparation are disclosed. Further disclosed are methods of making biologically active compounds of formula (I) as well as pharmaceutically acceptable compositions comprising compounds of formula (I). Compounds of formula (I) as disclosed herein can be used in a variety of applications including use as antibacterial agents.

THERAPEUTIC AGENT FOR RESPIRATORY DISEASE CONTAINING 4-HYDROXYPIPERIDINE DERIVATIVE AS ACTIVE INGREDIENT

An agent for preventing/treating respiratory diseases contains, as an active ingredient, a compound represented by following Formula (I): wherein A is a group represented by L-W [wherein L is a bond or CH2; and W is O, SOn (wherein n is 0 to 2), or -NR7-(wherein R7 is hydrogen or lower alkyl)]; each of G1 and G2 is (CH2)r (wherein r is 0 to 2), provided that when n is 1, G1 and G2 may be bridged by lower alkylene; Y is a lower alkylene or (substituted) benzylidene; Z is a bond or O, provided that when Z is a bond, Y may form a 5- or 6-membered ring with carbon on the benzene ring; R1 is, for example, NO2, a lower alkoxycarbonyl, (substituted) carbamoyl, (protected) hydroxyl group, (protected) carboxyl, or (protected) N-hydroxycarbamoyl; each of R2and R3 is hydrogen, halogen, (halogenated) lower alkyl, (halogenated) lower alkoxy or NO2; each of R4 and R5 is, for example, hydrogen, halogen, (halogenated) lower alkyl, (halogenated) lower alkoxy, CN, or lower alkylsulfonyl; and R6 is hydrogen or lower alkyl, a salt thereof or a solvate of them. It has excellent antitussive activity when used as an agent for preventing/treating respiratory diseases such as lung cancer, common cold syndrome, pulmonary tuberculosis, pneumonia, acute bronchitis or chronic bronchitis.

NOVEL ALKYNE COMPOUNDS EXHIBITING AN MCH ANTAGONISTIC EFFECT AND DRUGS CONTAINING SAID COMPOUNDS

The invention relates to an alkyne compound of general formula (I) in which A, B, W, X, Y, Z, R and R groups and residuals have the meanings given in claim 1. Drugs containing at least one type of inventive alkyne are also disclosed. The inventive drugs exhibiting an MCH-receptor antagonistic activity are suitable for treating metabolic disturbances and/or eating disorders, in particular adiposity, bulimia, anorexia, hyperphagia and diabetes.

Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds

The present invention relates to alkyne compounds of general formula I wherein the groups and radicals A, B, W, X, Y, Z, R1 and R2 have the meanings given in claim 1. Moreover the invention relates to pharmaceutical compositions containing at least one alkyne according to the invention. By virtue of their MCH-receptor antagonistic activity the pharmaceutical compositions according to the invention are suitable for the treatment of metabolic disorders and/or eating disorders, particularly obesity and diabetes.

NOVEL ALKYNE COMPOUNDS WITH AN MCH-ANTAGONISTIC ACTION AND MEDICAMENTS CONTAINING SAID COMPOUNDS

The invention relates to alkyne compounds of general formula (I), in which the groups and radicals A, B, W, X, Y, Z, R1 and R2 are defined as cited in claim 1. The invention also relates to medicaments containing at least one inventive alkyne. As a result of the antagonistic action against the MCH-receptor, the inventive medicaments are suitable for treating metabolic disorders and/or eating disorders, in particular adiposity and diabetes.

Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds

Alkyne compounds of formula I wherein A, B, W, X, Y, Z, R1, and R2 have the meanings given herein, which have MCH-receptor antagonistic activity and are useful for preparing pharmaceutical compositions for the treatment of metabolic disorders and/or eating disorders, particularly obesity and diabetes.

4-HYDROXPIPERIDINE DERIVATIVE WITH ANALGETIC ACTIVITY

A compound represented by the following Formula (I): (wherein A represents oxygen atom or -NR3- (R3 represents hydrogen atom or lower alkyl group); R1 represents nitro group, lower alkoxycarbonyl group, carbamoyl group unsubstituted or mono- or di-substituted by lower alkyl group, unprotected or protected hydroxyl group, unprotected or protected carboxyl group, lower alkyl group substituted by unprotected or protected hydroxyl group, or tetrazolyl group; and R2 represents hydrogen atom, cyano group or lower alkylsulfonyl group, provided that when A is - NR3-, it is excluded that R1 represents unprotected or protected hydroxyl group or lower alkyl group substituted by unprotected or protected hydroxyl group) or its salt, and method for producing the compound, and a pharmaceutical composition containing the compound as active ingredient.